TABLE 2.
Changes in blood pressure from baseline to week 8.
| Variable | TRE (No. = 33) | RE (No. = 31) | T (No. = 32) |
|---|---|---|---|
| MSSBP | |||
| Mean (SD) | −23.80 (12.82) | −7.18 (15.94) | −12.97 (15.28) |
| Treatment difference | |||
| LS mean (SE) | −23.02 (3.04) | −7.18 (3.09) | – |
| LS mean (SE) | −25.80 (2.74) | – | −14.92 (2.65) |
| LS mean difference [95% CI] | – | −15.85 [−23.00, −8.69] | −10.88 [−17.40, −4.36] |
| p † | – | <.0001 | .0015 |
| MSDBP | |||
| Mean (SD) | −11.00 (7.87) | −0.50 (8.63) | −6.56 (7.22) |
| Treatment difference | |||
| LS mean (SE) | −10.89 (1.49) | −1.15 (1.50) | – |
| LS mean (SE) | −12.27 (1.50) | – | −6.58 (1.46) |
| LS mean difference [95% CI] | – | −9.74 [−13.24, −6.24] | −5.68 [−9.31, −2.06] |
| p † | – | <.0001 | .0026 |
Treatment difference was calculated as telmisartan/rosuvastatin/ezetimibe group minus rosuvastatin/ezetimibe group or telmisartan group.
Abbreviations: CI, Confidence Interval; LS mean, Least Square Mean; MSSBP, mean sitting systolic blood pressure; MSDBP, mean sitting diastolic blood pressure; SD, Standard Deviation; SE, Standard Error; RE, rosuvastatin/ezetimibe; T, telmisartan; TRE, telmisartan/rosuvastatin/ezetimibe.
†
p value for ANCOVA, with Group(stratification variable) as a covariate.